AstraZeneca PLC (AZN) research: valuation against peers, fundamentals over time, risk and news coverage
AZN
AstraZeneca PLCNo data in this window.
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
- BREAKING STORYNEUTRALAstraZeneca Scraps Volrustomig Lung Trial as Enhertu Data Offsets Pipeline Setback
AstraZeneca discontinued a Phase 3 trial of volrustomig in lung cancer following disappointing data, a meaningful blow to its next-generation immuno-oncology ambitions. The negative headline was cushioned by positive progression-free survival results for Enhertu in a lung cancer setting, and shares traded higher as investors weighted the commercial-stage readout more heavily than the pipeline write-down.
Every figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.